Spermidine

Phase 3Small molecule

MMedical University of Graz

Spermidine is one of 83 small molecule programs targeting Hypertension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypertensionActive, not recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

Obesity & OverweightRecruiting

HypertensionPhase 3

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 1/Phase 2

Active, not recruiting

Obesity & OverweightPreclinical

Recruiting

Competition

Competitive Landscape

566 competitors in Hypertension

#DrugCompanyPhaseTrials

Spermidine

MMedical University of Graz

Phase 3

1 2

Edarbi

Takeda

Preclinical

10 3

Benicar

Novartis

Preclinical

7 4

Edarbi

Takeda

Preclinical

4 5

Aceon

Institut de Recherches Internationales Servier

Preclinical

5 6

Alphagan

Winrevair

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

2 9

Avastin

BBio-Thera Solutions

Preclinical

1 10

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalRecruiting

Obesity & Overweight

NCT07662330

Clinical

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma1 trial

A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)

Recruiting·WWest China Hospital·Phase 1/2·NCT07035626·58 enrolled

Hypertension1 trial

Spermidine Anti-Hypertension Study

Unknown status·MMedical University of Graz·Phase 3·NCT04405388·46 enrolled

Obesity & Overweight1 trial

Assessment of the Effects and Safety of Spermidine Supplementation on Blood Lipids and Body Weight in Overweight or Obese Individuals With Hyperlipidemia: A Randomized, Double-Blind, Placebo-Controlled Trial

Recruiting·SShanghai 10th People's Hospital·Preclinical·NCT07662330·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Spermidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Spermidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Spermidine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Graz company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMedical University of Graz

Spermidine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Head and Neck Squamous Cell Carcinoma1 trial

Hypertension1 trial

Obesity & Overweight1 trial

References

Drug Info

Quick Facts

Related News